|
|
22 May 2013 |
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Annual General Meeting
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today at the offices of Investec Bank plc, 2 Gresham Street, London, EC2V 7QP.
AMS is trading in line with market expectations for 2013. Due to the timing of the AGM, a more detailed pre-close trading statement will be released in late June.
Chris Meredith, AMS’s Chief Executive Officer, will give a presentation at the Annual General Meeting, the slides from which will be made available on the Company’s website www.admedsol.com. No new material information will be provided.
– ends –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director |
|
|
|
|
|
Tavistock Communications |
Tel: +44 (0) 20 7920 3150 |
|
John West / Chris Munden / Andrew Dunn |
|
|
|
|
|
Investec Bank plc |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence / Daniel Adams / Patrick Robb |
|
About Advanced Medical Solutions Group plc
Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.
AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer (“OEM”) customers around the world, but the majority of the Group’s revenues now come from its own brands – ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally through partnerships with its OEM customers.
AMS’s products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.
With 450 employees operating under four distinct business units that match its multiple products and routes-to-market (Branded Direct, Branded Distributed, OEM and Bulk Materials), AMS’s products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.
This information is provided by RNS
END
AGMSEEFWFFDSEFI